RxDoctor Payments Data

Anitha George

Family · Huntingdon Valley, PANPI 1760813133

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 24 payments — averaging $42.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Parapro, LLC$500
  • Amgen$207
  • Genentech USA, Inc.$156
  • Lilly USA, LLC$74
  • Pfizer$39
  • Phadia US Inc.$26
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$50049%
  • Food & beverage$51751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,040
Medicare patients
31
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$45,660
JanuviaSitagliptin Phosphate35$32,497
JanumetSitagliptin Phos/Metformin Hcl26$20,125
EliquisApixaban14$12,560
XareltoRivaroxaban13$11,771
FarxigaDapagliflozin Propanediol18$10,224
Breo ElliptaFluticasone/Vilanterol26$9,638
Tresiba Flextouch U-200Insulin Degludec14$9,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,047
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp25$4,492
VascepaIcosapent Ethyl16$3,885
Novolog FlexpenInsulin Aspart13$3,450
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$3,241
Fenofibrate21$2,445
Advair DiskusFluticasone Propion/Salmeterol12$2,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$12,56014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Huntingdon Valley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →